British Journal of Cancer · 2009 · 20 citations · 7 references
MedicineOncologyPharmacoeconomicsBreast OncologyCost-effectiveness AnalysisOutcomes ResearchAdjuvant TherapyBreast Cancer RecurrenceBreast SurgeryBreast-conserving TherapyCost-effectiveness ModelingHealthcare Cost AnalysisCancer Cost BurdenCost-effectivenessEconomic Burden Of CancerRetrospective Cost AnalysisTotal Annualized CostTreatment Cost Analysis
The complete hospital and community records of 77 women were randomly selected from 232 women who had relapsed breast cancer between 2000 and 2005. Scrutiny of all management activities revealed a total cost of 1,939,329 pound sterling (mean per patient of 25,186 pound sterling , 95% CI 13,705 pound sterling-33,821 pound sterling ). The median survival from time of relapse was 40.07 months and the median total cost per patient was 31 402.62 pound sterling . Including the community cost of a relapse provides a more realistic figure for future cost-effectiveness analysis of adjuvant breast cancer therapies.
7
Jean‐Marc Nabholtz, Aman U. Buzdar, Michaël Pollak et al. · Journal of Clinical Oncology · 2000 · 996 citations
Pharmacy, Oncology, Pharmacotherapy +15
M. Bontenbal, Geert‐Jan Creemers, Hans J. Braun et al. · Journal of Clinical Oncology · 2005 · 102 citations · Full text
Medicine, Oncology, Pharmacology +15